Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > NanoLogix Applies for Provisional Patent Application For Innovative Treatment of Severe Sepsis

NanoLogix, Inc. (PINKSHEETS: NNLX) announced today that it has filed a provisional patent application with the U.S. Patent Office titled, "Antimicrobial Action of a Silver-Coated Nanotubular Dialysis Device."

NanoLogix Applies for Provisional Patent Application For Innovative Treatment of Severe Sepsis

SHARON, PA | Posted on February 20th, 2007

This provisional patent application is based around a new and unique methodology for treating severe sepsis and septic shock. The incidence of severe sepsis and septic shock is the major factor in over two hundred thousand deaths per year in the United States. During the past decades billions of dollars have been spent in developing treatment strategies for this major cause of morbidity and mortality. Almost all treatment strategies have been centered around the utilization of intravenous antibiotics. However, even today 20-35% of patients with severe sepsis and 40-60% of patients with septic shock die within thirty days, with further deaths occurring within the first six months of illness. Due to the fact that almost all of these patients must be treated in intensive care units, the cost of treating a single patient costs up to $10,000 per day, and the total cost to the American health care system is many billions of dollars per annum.

The NanoLogix invention treats bacteremia and septic shock by utilizing a silver nanoparticle-coated nanotubular dialysis unit for killing pathogenic micro-organisms present in a patient's blood stream. Prior to making this application NanoLogix scientists investigated this novel methodology against two bacterial strains (E.coli and Staphylococcus aureus) and one fungal strain (Candida albicans). In multiple experiments the pathogenic load of the micro-organisms went from colonies that were too numerous to count, down to zero or a very dramatically reduced number of colonies.

Mitchell S. Felder, M.D., the CEO and Chairman of the Board of NanoLogix, Inc. stated, "This is both a fascinating as well as truly innovative approach to conquering this major cause of hospital deaths worldwide. We hope to accelerate our investigation of this methodology, and are currently seeking to partner with a major university and/or health care organization. With further success and development, this technique could truly revolutionize the treatment of infectious diseases and save countless lives."


About NanoLogix
NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer. For more information on the Company, visit

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please click here

Investor Relations.
Andrew Barwicki

Copyright © Market Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Nanoparticles simplify DNA identification and quantification November 27th, 2015

Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015

Electric fields remove nanoparticles from blood with ease November 24th, 2015

Production of Nanocapsules Containing Omega-3 Powder in Iran November 24th, 2015


Overtaking science fiction with physics: 33-year-old physicist at the University of Kaiserslautern receives 1.5 million euros of EU funding November 29th, 2015

'Material universe' yields surprising new particle November 28th, 2015

Iranian Scientists Discover New Catalyst to Remove Pharmaceutical Compounds from Wastewater November 28th, 2015

RAMAN Spectrometry Makes Characterization of Various Nanostructures Possible November 28th, 2015

Patents/IP/Tech Transfer/Licensing

Electric fields remove nanoparticles from blood with ease November 24th, 2015

Calling All Industries: Get Your Graphene By The Kiloton November 21st, 2015

Nanotech-based sensor developed to measure microRNAs in blood, speed cancer detection November 19th, 2015

Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA November 16th, 2015


Stanford technology makes metal wires on solar cells nearly invisible to light November 27th, 2015

Tandem solar cells are simply better: Higher efficiency thanks to perovskite magic crystal November 24th, 2015

ORNL microscopy captures real-time view of evolving fuel cell catalysts November 21st, 2015

NREL research identifies increased potential for perovskites as a material for solar cells November 21st, 2015


Electric fields remove nanoparticles from blood with ease November 24th, 2015

Using light-force to study single molecules November 23rd, 2015

Breakthrough allows tracking of single molecules in 3-D with nanoscale accuracy:New method builds on Nobel Prize-winning technique, with exciting implications for understanding the inner workings of cells and neurons November 23rd, 2015

New EU project designed to link diagnosis and treatment of diseases over the long term: Joint research project aims at the improvement of companion diagnostics and therapy of tumor diseases November 23rd, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

Car Brands
Buy website traffic